By Paul R. La Monica
Real estate stocks have been winners in this oil- and Iran-obsessed volatile stock market. That bodes well for Janus Living, a senior housing real estate investment trust that is set to debut Friday morning.
Janus Living, a carve-out of medical REIT Healthpeak Properties, priced its initial public offering at $20 a share, the high end of its projected range. The company also upped the size of its stock sale, from 37 million shares to 42 million shares. Janus Living is raising $840 million from the IPO and would be valued at $5.1 billion at the $20 price. The stock will trade with the ticker symbol of JAN on the New York Stock Exchange.
Investors love the big dividends. Healthpeak, which will still own more than 80% of Janus Living following the IPO, pays a dividend that yields nearly 7% for example.
But a separation of Janus into a stand-alone entity also makes sense. Senior living real estate investment trusts in particular have done well thanks to strong demographic trends as more baby boomers reach retirement age. Welltower and Ventas are both up more than 10% this year. Welltower pays a dividend that yields nearly 1.5% while Ventas sports a yield of 2.4%.
Janus Living will be an even better option for income-seeking investors though. According to a filing with the Securities and Exchange Commission, the company plans to pay a quarterly dividend of 14.25 cents a share. That works out to 57 ccnts annually and based on the $20 IPO price, the dividend yield would be about 2.9%.
Janus, which operates 34 senior living communities in 10 states, has a particularly big presence in the retirement hotbeds of Florida and Texas. Nearly 70% of its units are located in those two states. The company is profitable, posting net income of about $6.3 million in 2025 following a loss of more than $50 million a year earlier. Revenue rose 6% last year to $604 million.
Janus is going public during a seasonally slow time for IPOs. There has been a lull in the new issue market over the past few weeks following a flurry of deals in the first two months of 2026.
One exception? Drone tech company Swarmer wowed Wall Street with Triple-digit percentage gains earlier this week. But that can be chalked up to the fact that Swarmer sold a tiny amount of shares (3 million) and at a super low price of $5 a share.
Other IPOs have faced mixed receptions this year. Consumer stocks Once Upon a Farm and Bob's Discount Furniture have slid following promising starts. But biotechs Veradermics and SpyGlass Pharma have surged. Energy infrastructure companies SOLV and Forgent Power Solutions have also enjoyed impressive debuts.
The performance of several of this year's deals so far is a relatively promising sign following a solid year for IPOs in 2025. And investors are eagerly awaiting more (and much bigger) deals ahead. Elon Musk's SpaceX and artificial-intelligence giants OpenAI and Anthropic are likely to file for IPOs at some point in 2026. Investors are also watching for potential listings from Databricks and payments giant Stripe.
Write to Paul R. La Monica at paul.lamonica@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
March 20, 2026 11:46 ET (15:46 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments